Senate Bill 2323, also known as House Bill 2101, amends various provisions of the Tennessee Code Annotated related to the regulation of drugs, specifically focusing on the sale of products containing pseudoephedrine and ephedrine. Key changes include the requirement for pharmacies to implement an electronic sales tracking system by January 1, 2012, to monitor the sale of these products. The bill mandates that pharmacies electronically submit required information before completing sales and provides immunity from civil liability for pharmacies that comply with the system, barring any negligence or misconduct. Additionally, the bill establishes a fee structure for manufacturers of ephedrine and pseudoephedrine products, which will be assessed monthly starting January 1, 2027.

The bill also updates the definitions and terminology used in the existing law, replacing references to "NPLEx" with "electronic sales tracking system" and clarifying the roles of the administrator of this system. It increases the maximum allowable purchase limit of these products from 43.2 grams to 61.2 grams. Furthermore, the bill outlines the responsibilities of the Tennessee Bureau of Investigation (TBI) in notifying the electronic sales tracking system about individuals placed on the methamphetamine registry, ensuring that those individuals are flagged and prohibited from purchasing nonexempt products. The act is set to take effect on July 1, 2026.

Statutes affected:
Introduced: 39-17-431(c)(4), 39-17-431, 39-17-431(d), 39-17-431(e), 39-17-431(i), 39-17-431(j)(1), 39-17-431(j)(2), 39-17-431(l), 39-17-431(o), 39-17-431(c)